Jones Jefferson M, Agarwal Avinash, Moorman Anne C, Hofmeister Megan G, Hulse John C, Meneveau Max O, Mixon-Hayden Tonya, Ramachandran Sumathi, Jones Christopher M, Kellner Stephanie, Ferrell Daniel, Sifri Costi D
Division of Healthcare Quality Promotion, National Center for Emerging, Zoonotic and Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA.
Division of Transplantation, Department of Surgery, UVA Health, Charlottesville, VA.
Transplant Direct. 2023 Jul 12;9(8):e1506. doi: 10.1097/TXD.0000000000001506. eCollection 2023 Aug.
Donor-derived transmission of infections is a rare complication of kidney transplant. Hepatitis A virus (HAV) is a common cause of acute viral hepatitis worldwide, but donor-derived transmission to organ recipients has been reported in the literature only twice previously. The timeline for HAV incubation and clearance in transplant recipients is not well understood.
In 2018, 2 kidneys and a liver were procured from a deceased donor resident of Kentucky, one of many states that was experiencing an HAV outbreak associated with person-to-person transmission through close contact, primarily among people who reported drug use. Both kidney recipients, residents of Virginia, subsequently developed acute HAV infections. We report the results of an investigation to determine the source of transmission and describe the clinical course of HAV infection in the infected kidney recipients.
The liver recipient had evidence of immunity to HAV and did not become infected. The donor and both kidney recipients were found to have a genetically identical strain of HAV using a next-generation sequencing-based cyber molecular assay (Global Hepatitis Outbreak Surveillance Technology), confirming donor-derived HAV infections in kidney recipients. At least 1 kidney recipient experienced delayed development of detectable hepatitis A anti-IgM antibodies. By 383 and 198 d posttransplant, HAV RNA was no longer detectable in stool specimens from the left and right kidney recipients, respectively.
Adherence to current guidance for hepatitis A vaccination may prevent future morbidity due to HAV among organ recipients. http://links.lww.com/TXD/A548.
供体传播感染是肾移植罕见的并发症。甲型肝炎病毒(HAV)是全球急性病毒性肝炎的常见病因,但此前文献中仅报道过两例供体传播给器官受者的情况。移植受者中HAV的潜伏期和清除时间尚不清楚。
2018年,从肯塔基州一名已故供体获取了2个肾脏和1个肝脏,肯塔基州是众多经历HAV暴发的州之一,此次暴发与人与人之间通过密切接触传播有关,主要发生在报告有吸毒行为的人群中。两名肾脏受者均为弗吉尼亚州居民,随后均发生了急性HAV感染。我们报告了一项调查结果,以确定传播来源,并描述受感染肾脏受者中HAV感染的临床过程。
肝脏受者有HAV免疫证据,未被感染。使用基于下一代测序的网络分子检测方法(全球肝炎暴发监测技术)发现,供体和两名肾脏受者的HAV毒株基因相同,证实肾脏受者的HAV感染源自供体。至少有一名肾脏受者可检测到的甲型肝炎抗IgM抗体出现延迟。移植后383天和198天,左、右肾脏受者粪便标本中分别不再能检测到HAV RNA。
遵守当前甲型肝炎疫苗接种指南可能预防器官受者未来因HAV感染而发病。http://links.lww.com/TXD/A548